medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2021-22-25-30medalphabet-2233Research ArticleСтатьиТрудности и пути их преодоления при подборе терапии болевых синдромов у больных сахарным диабетомDiffculties and ways to overcome them in selection of therapy for pain syndromes in patients with diabetes mellitushttps://orcid.org/0000-0002-2140-0033МахиновК. А.MakhinovK. A.

 Махинов Константин Алексеевич, врач-невролог

Москва

 Makhinov Konstantin A., neurologist 

Moscow

https://orcid.org/0000-0001-6747-3476КамчатновП. Р.KamchatnovP. R.

 Камчатнов Павел Рудольфович, д.м.н., проф. кафедры неврологии, нейрохирургии и медицинской генетики

Москва

 Kamchatnov Pavel R., DM Sci, prof. Department Neurology, Neurosurgery and Medical Genetics 

Moscow

pavkam7@gmail.comАО «Европейский медицинский центр»РоссияJC ″European Medical Centre″Russian FederationФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава РоссииРоссияPirogov Russian National Research Medical UniversityRussian Federation202128092021022Неврология и психиатрия (3)2530Copyright © Махинов К.А., Камчатнов П.Р., 20212021Махинов К.А., Камчатнов П.Р.Makhinov K.A., Kamchatnov P.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2233

Сахарный диабет (СД) вызывает повреждение различных систем организма, в том числе, периферической нервной системы. Рассматриваются основные варианты поражения периферических нервов при СД. Приводятся сведения о развитии такого рода поражения, в частности, о формировании нейропатического болевого синдрома. Анализируются терапевтические возможности препаратов из различных фармакологических групп для лечения пациентов с неврологическими осложнениями СД.

Diabetes mellitus (DM) causes damage to various body systems, including the peripheral nervous system. The main variants of peripheral nerve damage in diabetes mellitus are considered. Information on the development of this kind of lesion, in particular, on the formation of neuropathic pain syndrome, is given. The therapeutic possibilities of drugs from various pharmacological groups for the treatment of patients with neurological complications of diabetes are analyzed.

сахарный диабетдиабетическая полинейропатиянейропатический болевой синдромлечениеантидепрессантыпротивоэпилептическиеdiabetes mellitusdiabetic polyneuropathyneuropathic pain syndrometreatmentantidepressantsantiepileptic drugseffcacyReferencesДедов И.И., Шестакова М.В., Викулова О.К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический анализ по данным Федерального регистра сахарного диабета. Сахарный диабет. 2017; 20 (1): 13–41. DOI: 10.14341/DM8664.Dedov I.I., Shestakova Ma.V., Vikulova O.K. Epidemiology of diabetes mellitus in Russian Federation: clinical and statistical report according to the federal diabetes registry. Diabetes Mellitus. 2017; 20 (1): 13–41. (In Russ.)Guariguata L., Whiting D. R., Hambleton I. et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014 Feb; 103 (2): 137–49. DOI: 10.1016/j.diabres.2013.11.002.Guariguata L., Whiting D. R., Hambleton I. et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014 Feb; 103 (2): 137–49. DOI: 10.1016/j.diabres.2013.11.002.International Association for the study of Pain. IASP Terminology – IASP [Internet]. www.iasppain.org/terminology? Accessed 4 Oct 2020.International Association for the study of Pain. IASP Terminology – IASP [Internet]. www.iasppain.org/terminology? Accessed 4 Oct 2020.Кукушкин М.Л., Яхно Н.Н., Чурюканов М.В. и соавт. Ноципластическая боль – новый дескриптор или упрощенный взгляд на проблему боли? Российский журнал боли. 2018; 2: 268–270.Kukushkin M. L., Yakhno N. N., Churyukanov M. V. et al. Notifcations pain – the new descriptor or simplistic view of the problem of pain? Russian Journal of Pain. 2018; 2: 268–270. (In Russ.)Busui R.P., Boulton A.J.M., Feldman E.L. et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association Diabetes Care 2017; 40: 136–154. DOI: 10.2337/dc16–2042.Busui R.P., Boulton A.J.M., Feldman E.L. et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association Diabetes Care 2017; 40: 136–154. DOI: 10.2337/dc16–2042.Stierli S., Imperatore V., Lloyd A. Schwann cell plasticity–roles in tissue homeostasis, regeneration, and disease. Glia. 2019 Nov; 67 (11): 2203–2215. DOI: 10.1002/glia.23643.Stierli S., Imperatore V., Lloyd A. Schwann cell plasticity–roles in tissue homeostasis, regeneration, and disease. Glia. 2019 Nov; 67 (11): 2203–2215. DOI: 10.1002/glia.23643.Callaghan B., Cheng H., Stables C., et al. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012; 11: 521. DOI: 10.1016/S1474–4422(12)70065–0.Callaghan B., Cheng H., Stables C., et al. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012; 11: 521. DOI: 10.1016/S1474–4422(12)70065–0.Ritzwoller DP, Ellis JL, Korner EJ, Hartsfeld CL, Sadosky A. Comorbidities, healthcare service utilization and costs for patients identifed with painful DPN in a managed-care setting. Curr Med Res Opin. 2009 Jun; 25 (6): 1319–28. DOI: 10.1185/03007990902864749.Ritzwoller DP, Ellis JL, Korner EJ, Hartsfeld CL, Sadosky A. Comorbidities, healthcare service utilization and costs for patients identifed with painful DPN in a managed-care setting. Curr Med Res Opin. 2009 Jun; 25 (6): 1319–28. DOI: 10.1185/03007990902864749.Papanas N, Ziegler D. Prediabetic neuropathy: does it exist? Curr Diab Rep. 2012 Aug; 12 (4): 376–83. DOI: 10.1007/s11892–012–0278–3.Papanas N, Ziegler D. Prediabetic neuropathy: does it exist? Curr Diab Rep. 2012 Aug; 12 (4): 376–83. DOI: 10.1007/s11892–012–0278–3.Ziegler D., Hanefeld M., Ruhnau K. et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant lipoic acid. Diabetologia. 1995; 38 (12): 1425–33. DOI: 10.1007/BF00400603.Ziegler D., Hanefeld M., Ruhnau K. et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant lipoic acid. Diabetologia. 1995; 38 (12): 1425–33. DOI: 10.1007/BF00400603.Ziegler D., Ametov A., Barinov A. et al. Oral treatment with lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY2 trial. Diabetes Care. 2006; 29 (11): 2365–70. DOI: 10.2337/dc06–1216.Ziegler D., Ametov A., Barinov A. et al. Oral treatment with lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY2 trial. Diabetes Care. 2006; 29 (11): 2365–70. DOI: 10.2337/dc06–1216.Ziegler D, Nowak H, Kempler P. et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004; 21 (2): 114–121. DOI: 10.1111/j.1464–5491.2004.01109.xZiegler D, Nowak H, Kempler P. et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004; 21 (2): 114–121. DOI: 10.1111/j.1464–5491.2004.01109.xMijnhout G., Kollen B., Alkhalaf A. et al. Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. Int J Endocrinol. 2012; 2012: 456279; DOI: 10.1155/2012/456279.Mijnhout G., Kollen B., Alkhalaf A. et al. Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. Int J Endocrinol. 2012; 2012: 456279; DOI: 10.1155/2012/456279.Head KA. Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Altern Med Rev. 2006; 11: 294–329.Head KA. Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Altern Med Rev. 2006; 11: 294–329.Ang C., Alviar M., Dans L. et al. Vitamin B for treating peripheral neuropathy. Cochrane Database Syst Rev. 2008 Jul 16; (3): CD004573. DOI: 10.1002/14651858.CD004573.pub3.Ang C., Alviar M., Dans L. et al. Vitamin B for treating peripheral neuropathy. Cochrane Database Syst Rev. 2008 Jul 16; (3): CD004573. DOI: 10.1002/14651858.CD004573.pub3.Sawangjit R., Thongphui S., Chaichompu W., Phumart P. Effcacy and Safety of Mecobalamin on Peripheral Neuropathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Altern Complement Med. 2020. Dec; 26 (12): 1117–1129. DOI: 10.1089/acm.2020.0068. Epub 2020 Jul 21.Sawangjit R., Thongphui S., Chaichompu W., Phumart P. Effcacy and Safety of Mecobalamin on Peripheral Neuropathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Altern Complement Med. 2020. Dec; 26 (12): 1117–1129. DOI: 10.1089/acm.2020.0068. Epub 2020 Jul 21.Karaganis S., Song X. B vitamins as a treatment for diabetic pain and neuropathy. J Clin Pharm Ther. 2021 Feb 9. DOI: 10.1111/jcpt.13375. Online ahead of print.Karaganis S., Song X. B vitamins as a treatment for diabetic pain and neuropathy. J Clin Pharm Ther. 2021 Feb 9. DOI: 10.1111/jcpt.13375. Online ahead of print.Finnerup N.B., Attal N., Haroutounian S. et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015 Feb; 14 (2): 162–73. DOI: 10.1016/S1474–4422(14)70251–0.Finnerup N.B., Attal N., Haroutounian S. et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015 Feb; 14 (2): 162–73. DOI: 10.1016/S1474–4422(14)70251–0.Камчатнов П.Р., Евзельман М.А., Абусуева Б.А., Волков А.И. Капсаицин в лечении нейропатической боли. Журнал неврологии и психиатрии им. C.C. Корсакова. 2014; 114 (11): 135–144.Kamchatnov P.R., Evzelman M.A., Abusueva B.A., Volkov A.I. Capsaicin in treatment of neuropathic pain. Journal of Neurology and Psychiatry n.a. S.S. Korsakov. 2014; 114 (11): 135–144. (In Russ.)Mason L., Moore R., Derry S. et al. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ. 2004; 328 (7446): 991. DOI: 10.1136/bmj.38042.506748.EE.Mason L., Moore R., Derry S. et al. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ. 2004; 328 (7446): 991. DOI: 10.1136/bmj.38042.506748.EE.Bril V., England J., Franklin GM. et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011 May 17; 76 (20): 1758–65. DOI: 10.1212/WNL.0b013e3182166ebe.Bril V., England J., Franklin GM. et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011 May 17; 76 (20): 1758–65. DOI: 10.1212/WNL.0b013e3182166ebe.Argoff C., Galer BS, Jensen M. et al. Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the neuropathic pain scale. Curr Med Res Opin. 2004;20 Suppl 2: S21–S8. DOI: 10.1185/030079904X12960.Argoff C., Galer BS, Jensen M. et al. Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the neuropathic pain scale. Curr Med Res Opin. 2004;20 Suppl 2: S21–S8. DOI: 10.1185/030079904X12960.Barbano RL, Herrmann DN, Hart-Gouleau S. et al. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol. 2004; 61 (6): 914–8. DOI: 10.1001/archneur.61.6.914.Barbano RL, Herrmann DN, Hart-Gouleau S. et al. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol. 2004; 61 (6): 914–8. DOI: 10.1001/archneur.61.6.914.Simpson DA. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J Clin Neuromuscul Dis. 2001; 3 (2): 53–62. DOI: 10.1097/00131402–200112000–00002.Simpson DA. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J Clin Neuromuscul Dis. 2001; 3 (2): 53–62. DOI: 10.1097/00131402–200112000–00002.Gilron I., Bailey J., Tu D. et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomized controlled crossover trial. Lancet. 2010; 374 (9697): 1252–61. DOI: 10.1016/S0140–6736(09)61081–3.Gilron I., Bailey J., Tu D. et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomized controlled crossover trial. Lancet. 2010; 374 (9697): 1252–61. DOI: 10.1016/S0140–6736(09)61081–3.Bouhassira D., Wilhelm S., Schacht A. et al. Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: data from the randomized, double-blind, COMBO-DN study. Pain. 2014 Oct; 155 (10): 2171–9. DOI: 10.1016/j.pain.2014.08.020.Bouhassira D., Wilhelm S., Schacht A. et al. Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: data from the randomized, double-blind, COMBO-DN study. Pain. 2014 Oct; 155 (10): 2171–9. DOI: 10.1016/j.pain.2014.08.020.Yuan R., Sheu J., Yu J. et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology. 2009; 72: 1473–8. DOI: 10.1212/01.wnl.0000345968.05959.cf.Yuan R., Sheu J., Yu J. et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology. 2009; 72: 1473–8. DOI: 10.1212/01.wnl.0000345968.05959.cf.Chen W., Yuan R., Chiang S. et al. Onabotulinumtoxin A improves tactile and mechanical pain perception in painful diabetic polyneuropathy. Clin J Pain. 2013; 29: 305–10. DOI: 10.1097/AJP.0b013e318255c132.Chen W., Yuan R., Chiang S. et al. Onabotulinumtoxin A improves tactile and mechanical pain perception in painful diabetic polyneuropathy. Clin J Pain. 2013; 29: 305–10. DOI: 10.1097/AJP.0b013e318255c132.Provenzano D., Heller J., Hanes M. Current Perspectives on Neurostimulation for the Management of Chronic Low Back Pain: A Narrative Review. J Pain Res. 2021 Feb 17; 14: 463–479. DOI: 10.2147/JPR.S249580.Provenzano D., Heller J., Hanes M. Current Perspectives on Neurostimulation for the Management of Chronic Low Back Pain: A Narrative Review. J Pain Res. 2021 Feb 17; 14: 463–479. DOI: 10.2147/JPR.S249580.Taylor R., van Buyten J., Buscher E. Spinal cord stimulation for chronic back and leg pain and failed back surgery syndrome: a systematic review and analysis of prognostic factors. Spine. 2005; 30: 152–60. DOI: 10.1097/01.brs.0000149199.68381.fe.Taylor R., van Buyten J., Buscher E. Spinal cord stimulation for chronic back and leg pain and failed back surgery syndrome: a systematic review and analysis of prognostic factors. Spine. 2005; 30: 152–60. DOI: 10.1097/01.brs.0000149199.68381.fe.Abate M., Di Carlo L., Salini V., Schiavone C. Metabolic syndrome associated to non-inflammatory Achilles enthesopathy. Clin Rhuematol. 2014; 33: 1517–1522. DOI: 10.1007/s10067–014–2524–3.Abate M., Di Carlo L., Salini V., Schiavone C. Metabolic syndrome associated to non-inflammatory Achilles enthesopathy. Clin Rhuematol. 2014; 33: 1517–1522. DOI: 10.1007/s10067–014–2524–3.Wise B., Peloquin C., Choi H. et al. 2012; 125: 1228.e23–1228.e28. DOI: 10.1016/j.amjmed.2012.05.027.Wise B., Peloquin C., Choi H. et al. 2012; 125: 1228.e23–1228.e28. DOI: 10.1016/j.amjmed.2012.05.027.Papachristou S, Pafli K, Papanas N. Skin AGEs and diabetic neuropathy. BMC Endocr Disord. 2021 Feb 23; 21 (1): 28. DOI: 10.1186/s12902–021–00697–7.Papachristou S, Pafli K, Papanas N. Skin AGEs and diabetic neuropathy. BMC Endocr Disord. 2021 Feb 23; 21 (1): 28. DOI: 10.1186/s12902–021–00697–7.Dhumad M., Hamdan F., Khudhair M., Al-Matubsi H. Correlation of staging and risk factors with cardiovascular autonomic neuropathy in patients with type II diabetes mellitus. Sci Rep. 2021 Feb 11; 11 (1): 3576. DOI: 10.1038/s41598–021–80962-w.Dhumad M., Hamdan F., Khudhair M., Al-Matubsi H. Correlation of staging and risk factors with cardiovascular autonomic neuropathy in patients with type II diabetes mellitus. Sci Rep. 2021 Feb 11; 11 (1): 3576. DOI: 10.1038/s41598–021–80962-w.Moon S., Kim C., Kang S. et al. Status of Diabetic Neuropathy in Korea: A National Health Insurance Service-National Sample Cohort Analysis (2006 to 2015). Diabetes Metab J. 2021 Jan; 45 (1): 115–119. DOI: 10.4093/dmj.2020.0120.Moon S., Kim C., Kang S. et al. Status of Diabetic Neuropathy in Korea: A National Health Insurance Service-National Sample Cohort Analysis (2006 to 2015). Diabetes Metab J. 2021 Jan; 45 (1): 115–119. DOI: 10.4093/dmj.2020.0120.Freeman R. Diabetic autonomic neuropathy. Handb Clin Neurol 2014; 126: 63–79. DOI: 10.1016/B978–0–444–53480–4.00006–0.Freeman R. Diabetic autonomic neuropathy. Handb Clin Neurol 2014; 126: 63–79. DOI: 10.1016/B978–0–444–53480–4.00006–0.Jones K., Russo A., Stevens J. et al. Predictors of delayed gastric emptying in diabetes. Diabetes Care 2001; 24 (7): 1264–1269. DOI: 10.2337/diacare. 24.7.1264.Jones K., Russo A., Stevens J. et al. Predictors of delayed gastric emptying in diabetes. Diabetes Care 2001; 24 (7): 1264–1269. DOI: 10.2337/diacare. 24.7.1264.Camilleri M. Gastrointestinal motility disorders in neurologic disease. J Clin Invest.2021 Feb 15; 131 (4): e143771. DOI: 10.1172/JCI143771.Camilleri M. Gastrointestinal motility disorders in neurologic disease. J Clin Invest.2021 Feb 15; 131 (4): e143771. DOI: 10.1172/JCI143771.Marathe C., Jones K., Wu T. et al. Gastrointestinal autonomic neuropathy in diabetes. Auton Neurosci. 2020 Dec; 229: 102718. DOI: 10.1016/j.autneu.2020.102718.Marathe C., Jones K., Wu T. et al. Gastrointestinal autonomic neuropathy in diabetes. Auton Neurosci. 2020 Dec; 229: 102718. DOI: 10.1016/j.autneu.2020.102718.Kuźnik E., Dudkowiak R., Adamiec R., Poniewierka E. Diabetic autonomic neuropathy of the gastrointestinal tract. Prz Gastroenterol. 2020; 15 (2): 89–93. DOI: 10.5114/pg.2020.95554.Kuźnik E., Dudkowiak R., Adamiec R., Poniewierka E. Diabetic autonomic neuropathy of the gastrointestinal tract. Prz Gastroenterol. 2020; 15 (2): 89–93. DOI: 10.5114/pg.2020.95554.

The authors declare that there are no conflicts of interest present.